Table 3. Joint effects survival analysis of clinical factors and the DEMs’ signature risk score with OS in LUAD patients.
| Gene combination | Groups | Event/Total | MST | Crude HR(95%CI) | Crude P | Adjusted HR(95%CI) | Adjusted P& |
|---|---|---|---|---|---|---|---|
| MCM4+MCM5 | |||||||
| Group A | 50/180 | 1790 | 1 | 1 | |||
| Group B | 46/140 | 1600 | 1.341(0.898–2.003) | 1.151 | 1.203(0.797–1.816) | 0.378 | |
| Group C | 86/180 | 1073 | 2.069(1.459–2.935) | <0.0001 | 1.680(1.175–2.402) | 0.004 | |
| MCM4+MCM8 | |||||||
| Group a | 83/250 | 1725 | 1 | 1 | |||
| Group b | 25/74 | 1235 | 1.475(0.940–2.316) | 0.091 | 1.52(0.968–2.388) | 0.069 | |
| Group c | 74/176 | 1258 | 1.580(1.152–2.166) | 0.005 | 1.351(0.981–1.860) | 0.066 | |
| MCM5+MCM8 | |||||||
| Group i | 83/250 | 1725 | 1 | 1 | |||
| Group ii | 24/84 | 1501 | 1.094(0.692–1.728) | 0.7 | 1.071(0.677–1.694) | 0.77 | |
| Group iii | 75/166 | 1115 | 1.788(1.306–2.449) | <0.0001 | 1.541(1.120–2.120) | 0.008 | |
| MCM4+MCM5+MCM8 | |||||||
| Group I | 52/176 | 1790 | 1 | 1 | |||
| Group II | 69/195 | 1501 | 1.617(1.126–2.322) | 0.009 | 1.541(1.065–2.230) | 0.022 | |
| Group III | 61/129 | 1115 | 2.152(1.483–3.122) | <0.0001 | 1.766(1.206–2.585) | 0.003 |
Notes: &Adjusted for tumor stage. MST, median survival time; HR, hazard ratio; CI, confidence interval; NA, not available;MCM, minichromosome maintenance; LUAD, lung adenocarcinoma.